5,511 reports of this reaction
3.6% of all PEMBROLIZUMAB reports
#2 most reported adverse reaction
DEATH is the #2 most commonly reported adverse reaction for PEMBROLIZUMAB, manufactured by Merck Sharp & Dohme LLC. There are 5,511 FDA adverse event reports linking PEMBROLIZUMAB to DEATH. This represents approximately 3.6% of all 152,954 adverse event reports for this drug.
PEMBROLIZUMAB has an overall safety score of 88 out of 100. Patients taking PEMBROLIZUMAB who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is moderately reported among PEMBROLIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to death, the following adverse reactions have been reported for PEMBROLIZUMAB:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 5,511 FDA reports for PEMBROLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 3.6% of all adverse event reports for PEMBROLIZUMAB, making it one of the most commonly reported side effect.
If you experience death while taking PEMBROLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.